Navigation Links
Medical Marijuana Inc. Portfolio Company CanChew BioTechnologies Inc. Announces Final Three Days for Market Survey and Free Product Trial Registration
Date:11/13/2012

SAN DIEGO, Nov. 13, 2012 /PRNewswire/ -- CanChew BioTechnologies Inc, a portfolio company of Medical Marijuana Inc. (OTC: MJNA), announces that this week marks the final three days to register for the market trial of CanChew gum.  Qualifying participants will receive a minimum of a 30-day free trial sample of the CBD-based CanChew gum in exchange for their product feedback.  The only cost involved will be a nominal shipping charge of $4.95 for delivery of the product. 

While the company has been researching distribution partnerships for over-the-counter sales of the CanChew gum product, preparations for clinical trials have been underway in Europe and are slated to begin during 2013.  U.S. clinical trials should begin shortly thereafter.  Successful trials and new drug application may eventually lead to a European and/or U.S. pharmaceutical product with substantiated medical claims. Over the counter sales of CanChew gum are expected to begin in the first quarter of 2013. 

Ted Caligiuri, President and CEO of Medical Marijuana Inc. comments: "We are pleased with the interest in our CanChew market survey and free product trial and eagerly anticipate positive feedback from clients."

The gum contains high concentrations of CBD hemp oil and its raw ingredients are derived from the operations of PhytoSphere systems, an MJNA portfolio company.  MJNA anticipates selling these products through the Internet, as well portfolio company Red Dice Holdings national distribution platform. Currently, Red Dice Holdings distributes a variety of CBD Hemp oil products in over 500 retail locations throughout Colorado, Arizona, California and New Mexico.

Please visit this link to sign up for the market trial: http://www.canchewbiotech.com/component/users/?view=registration

About CanChew
CanChew® is a unique, socially acceptable, patient friendly, taste masked and convenient delivery format for delivery of cannabis/cannabinoid(s) based pharmaceuticals. The delivery of these medications via the oral mucosa provides for rapid and near complete absorption directly into the systemic circulation. This leads to rapid onset of effects and increased bioavailability. Pre-systemic metabolism is thus avoided. This system of delivery offers clearly improved economic opportunities compared to alternative drug delivery routes. 

About Medical Marijuana, Inc.                                                                                               Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value.

Medical Marijuana Inc. does not grow, sell or distribute any substances that violate United States Law or the controlled substance act.

For more information, please visit the company's website at: www.MedicalMarijuanaInc.com

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration (FDA). These products and statements are not intended to diagnose, treat, cure, or prevent any disease.

Corporate Contact:

Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc 
Investor Relations Contact:
Stuart T. Smith
SmallCapVoice.Com, Inc.
P. 512-267-2430
F. 512-267-2530
Email: ssmith@smallcapvoice.com
Skype: SmallCapVoice.com
AIM: SmallCapVoice7


'/>"/>
SOURCE Medical Marijuana Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Varian Medical Systems to Exhibit Flat Panel Detectors, X-Ray Tubes and Imaging Software Optimized for Digital Radiography at MEDICA
2. RPS Announces Jonathan M. Fishbein, MD as Executive Vice President and Chief Medical Officer
3. Dukes Ralph Snyderman, M.D. Joins SenGenix as Senior Medical Advisor and Board Member
4. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
5. Medical Device Study Presents Detailed View of Key Budget and Staffing Metrics for Marketing Groups
6. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
7. Sony Medical Division Teams with Wills Eye Institute to Bring "Expert" Panel of Ophthalmologists to AAO 2012 Convention
8. STD Med Inc. Receives ANVISA Registration for Class III Medical Devices in Brazil
9. Mount Sinai Medical Center 1st in Tri-State Area to Discharge Patient without Human Heart
10. Concord Medical Announces Change to Third Quarter Financial Results Date to November 20, 2012
11. Winner Medical Announces Mailing of Definitive Proxy Materials for Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Spain , Dec. 2, 2016 In ... natural sources apart from those derived from C. sativa, ... the Universita` di Napoli Federico II , the ... created the first comprehensive, critical, integrated and unified inventory ... The article focuses on the remarkable chemical and ...
(Date:12/2/2016)... Dec. 2, 2016  The Addiction Treatment Advisory ... of Managed Care Pharmacy (AMCP), has released detailed ... address the opioid addiction crisis, including through improved ... ATAG,s newly released paper, "The Role ... Naloxone," addresses many issues around gaps and barriers ...
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, LLC ... Pharmaceutical Specialties, Inc. ("PSI").  The combination of Texas ... Georgia -based PSI bring together both company,s clinical expertise ... and payers an industry-leading specialty pharmacy. About Maxor ... , , ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, a trusted name in ... trial program for all of the company’s desktop riser products. A simple application ... experience. , FlexiSpot’s unique desktop risers use an advanced dual gas spring hovering ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, ... ... today, featuring an inspirational interview of two ostomy patients, standing as living proof ... million people suffer from digestive diseases and issues that spike around the holidays. ...
(Date:12/2/2016)... Hawaii (PRWEB) , ... December 02, 2016 , ... ... 2016 at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering ... in the field of pain management. , The demand for supplemental training ...
(Date:12/2/2016)... , ... December 02, 2016 , ... "Pro3rd Accents Volume ... editors to create versatile lower third titles with just a few clicks of the ... Volume 2 includes 30 lower third animations. Choose from various styles with accented animations, ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative ... National Family Partnership and the Drug Enforcement Administration as part of the National Red ... 10 winning schools who decorated their campuses with this year’s Red Ribbon Week theme: ...
Breaking Medicine News(10 mins):